Mizuho Securities Upgrades Myriad Genetics (MYGN) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Stephens Resumes Myriad Genetics (MYGN) at Overweight
May 9, 2013 7:53 AM EDTStephens resumed coverage on Myriad Genetics (NASDAQ: MYGN) with an Overweight rating and a price target of $38.00.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more... More
Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 6c
May 7, 2013 4:29 PM EDTMyriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.46, $0.06 better than the analyst estimate of $0.40. Revenue for the quarter came in at $156.5 million versus the consensus estimate of $148.25 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.... More
